Correspondence 2457 natriuretic peptides are stored in solutions (0.9% saline, phosphate-buffered saline, etc), their storage life is markedly less. When stored for 6 months at -80TC, the biologic activity as reflected by natriuresis or diuresis when infused into animals8 or humans9 is no longer present in approximately 25% of the peptides thus stored. When this storage is continued for 8 months, 75% of the stored peptides no longer have biological activity. I hope this information will be useful to everyone with an interest in atrial natriuretic peptides. There was no evidence that ANP in dog plasma stored frozen up to 8 weeks undergoes degradation. Control plasma consistently contained levels of ANP between 30 and 40 pg/mL. Observed values from spiked samples were generally 80% to 90% of expected values. Solid-phase extraction efficiency, as determined by recovery of radiolabeled ANP from dog plasma, was 80% to 85% and readily accounted for the lower values observed. Plasma ANP levels were consistent and high (-250 pg/mL) in the CHF dog, from immediate extraction until 8 weeks of storage at -800C. ANP extracted from samples and refrozen at -800C in assay buffer was also stable for at least 1 month.
There was no evidence that ANP in dog plasma stored frozen up to 8 weeks undergoes degradation. Control plasma consistently contained levels of ANP between 30 and 40 pg/mL. Observed values from spiked samples were generally 80% to 90% of expected values. Solid-phase extraction efficiency, as determined by recovery of radiolabeled ANP from dog plasma, was 80% to 85% and readily accounted for the lower values observed. Plasma ANP levels were consistent and high (-250 pg/mL) in the CHF dog, from immediate extraction until 8 weeks of storage at -800C. ANP extracted from samples and refrozen at -800C in assay buffer was also stable for at least 1 month.
In our hands, ANP does not undergo significant degradation in plasma when collected and stored with fidelity to the procedure above. The results of Nelesen et al could be attributed to the methods used in their treatment of the blood. For example, in their heparin and EDTA storage regimens, was blood stored frozen as stated by the authors? More important, they added the protease inhibitor aprotinin to the plasma, not whole blood, as we and others have done, such that substantial proteolytic degradation of ANP may have occurred by the time plasma samples were stored. in which they stored samples with less than 30 pg/mL ANP, an amount that provides less than 25% displacement of the radiolabeled ANP in their assay. We stored samples with 200 pg/mL ANP, so that if the samples degraded, ANP levels would remain in the sensitive range of the assay.2 Therefore, the lack of degradation found by Vesely may be due primarily to the low concentration of the samples. Asaad et al claim no significant breakdown of ANP in dog plasma. Our study focused on human plasma samples. We made no claims as to these effects in other species. As to their questions of our methodology, the protease inhibitor was in blood collection tubes for that condition, and plasma, not whole blood, was frozen.
The concern expressed by these letters, as well as in the previous letters, is shared by us. Our findings are disconcerting for a dynamic field. The overall inconsistent findings that have been published, however, are just as disconcerting. As our study was done with three replications showing similar findings, we therefore stand by our findings that plasma ANP degrades during prolonged storage at -800C.2 We recommend that plasma ANP samples not be stored for prolonged periods warmer than -1960C and not be
